AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens  ¹     Remo Panaccione  ²     Julian Panés  ³     William Sandborn  ⁴     Brian G. Feagan  ⁵     Tadakazu Hisamatsu  ⁶     Peter Bossuyt  ⁷     Marc Ferrante  ⁸     Silvio Danese  ⁹     Ezequiel Neimark  ¹⁰     Alexandra Song  ¹⁰     Xiaomei Liao  ¹⁰     Tian Feng  ¹⁰     Rachel Duan  ¹⁰     Sofie Berg  ¹⁰     Kori Wallace  ¹⁰     Jean-Frédéric Colombel  ^11    
1 Amsterdam University Medical Center, Amsterdam, Netherlands
² University of Calgary, Calgary, Canada
³ Hospital Clínic Barcelona, Barcelona, Spain
⁴ University of California San Diego, San Diego, United States
⁵ Alimentiv Inc., London, Canada
⁶ Kyorin University School of Medicine, Tokyo, Japan
⁷ Imelda General Hospital, Bonheiden, Belgium
⁸ University Hospitals Leuven, Leuven, Belgium
⁹ IRCCS Humanitas Research Hospital and Hunimed, Rozzano, Italy
¹⁰ AbbVie Inc., North Chicago, United States
¹¹ Icahn School of Medicine at Mount Sinai, USA, United States

Topic
IBD, Immunology

Session
IBD: Clinical trials III

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)